Vaxart Files 8-K: Shareholder Votes, Reg FD, Financials
Ticker: VXRT · Form: 8-K · Filed: May 22, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | May 22, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, regulatory-filing
Related Tickers: VXRT
TL;DR
Vaxart dropped an 8-K covering shareholder votes, Reg FD, and financials. Check it out.
AI Summary
Vaxart, Inc. filed an 8-K on May 22, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements and exhibits as of May 21, 2025. The filing details the company's corporate structure and historical name changes, including its former names Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.
Why It Matters
This 8-K filing provides updates on key corporate actions and financial reporting for Vaxart, Inc., which could influence investor decisions regarding the company's governance and financial health.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Aviragen Therapeutics, Inc. (company) — Former Company Name
- Biota Pharmaceuticals, Inc. (company) — Former Company Name
- NABI BIOPHARMACEUTICALS (company) — Former Company Name
- May 21, 2025 (date) — Date of earliest event reported
- May 22, 2025 (date) — Filing Date
FAQ
What specific matters were submitted to a vote of Vaxart, Inc. security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What is the primary purpose of this 8-K filing for Vaxart, Inc.?
The primary purpose is to report on the submission of matters to a vote of security holders, Regulation FD disclosures, and financial statements and exhibits as of May 21, 2025.
When was Vaxart, Inc. incorporated, and in which state?
Vaxart, Inc. was incorporated in Delaware.
What are the historical former names of Vaxart, Inc. mentioned in the filing?
The filing mentions former names including Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.
What is Vaxart, Inc.'s business address and phone number?
Vaxart, Inc.'s business address is 170 Harbor Way, Suite 300, South San Francisco, CA 94080, and the business phone number is (650) 550-3500.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 22, 2025 regarding Vaxart, Inc. (VXRT).